These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28140083)

  • 1. Rituximab: Ongoing and future clinical development.
    Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
    Semin Oncol; 2002 Feb; 29(1S2):105-112. PubMed ID: 28140083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: ongoing and future clinical development.
    Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: an insider's historical perspective.
    Grillo-López AJ
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):9-16. PubMed ID: 11226006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.
    Theuer CP; Leigh BR; Multani PS; Allen RS; Liang BC
    Biotechnol Annu Rev; 2004; 10():265-95. PubMed ID: 15504711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
    Leonard JP; Link BK
    Semin Oncol; 2002 Feb; 29(1S2):81-86. PubMed ID: 28140096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1S2):25-29. PubMed ID: 28140088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1S2):70-74. PubMed ID: 28140094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma.
    Grillo-López AJ; Dallaire BK; McClure A; Weaver R; Varns C; Wei A; Allen R; Lee D; Shen D; Leonard J; Multani P; White CA
    Curr Pharm Biotechnol; 2001 Dec; 2(4):301-11. PubMed ID: 11762412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of rituximab, the new FDA-approved antibody.
    Leget GA; Czuczman MS
    Curr Opin Oncol; 1998 Nov; 10(6):548-51. PubMed ID: 9818234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in the treatment of diffuse large B-cell lymphomas.
    Coiffier B
    Semin Oncol; 2002 Feb; 29(1S2):30-35. PubMed ID: 28140089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma.
    White CA; Larocca A; Grillo-López AJ
    Pharm Sci Technol Today; 1999 Mar; 2(3):95-101. PubMed ID: 10322362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia.
    Nabhan C; Rosen ST
    Semin Oncol; 2002 Feb; 29(1S2):75-80. PubMed ID: 28140095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanuolides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
    Semin Oncol; 2002 Feb; 29(1S2):87-92. PubMed ID: 28140097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.
    Kunkel L; Wong A; Maneatis T; Nickas J; Brown T; Grillo-López A; Benyunes M; Grobman B; Dillman RO
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):53-61. PubMed ID: 11226001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
    Rastetter W; Molina A; White CA
    Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.